Niesvizky R - Search Results

1

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.

Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Martin P, et al. Among authors: niesvizky r. Ann Oncol. 2008 Jul;19(7):1327-1330. doi: 10.1093/annonc/mdn045. Epub 2008 Mar 17. Ann Oncol. 2008. PMID: 18349031 Free article.

2

BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia.

Coleman M, Leonard J, Lyons L, Pekle K, Nahum K, Pearse R, Niesvizky R, Michaeli J. Coleman M, et al. Among authors: niesvizky r. Leuk Lymphoma. 2002 Sep;43(9):1777-82. doi: 10.1080/1042819021000006303. Leuk Lymphoma. 2002. PMID: 12685831

3

Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone.

Coleman M, Leonard J, Lyons L, Szelenyi H, Niesvizky R. Coleman M, et al. Among authors: niesvizky r. Semin Oncol. 2003 Apr;30(2):270-4. doi: 10.1053/sonc.2003.50044. Semin Oncol. 2003. PMID: 12720151 Clinical Trial.

4

The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation.

Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, Chen YT, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ. Jungbluth AA, et al. Among authors: niesvizky r. Blood. 2005 Jul 1;106(1):167-74. doi: 10.1182/blood-2004-12-4931. Epub 2005 Mar 10. Blood. 2005. PMID: 15761016 Free article.

5

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM. Leonard JP, et al. Among authors: niesvizky r. J Clin Oncol. 2005 Aug 1;23(22):5044-51. doi: 10.1200/JCO.2005.13.821. Epub 2005 Jun 13. J Clin Oncol. 2005. PMID: 15955901 Clinical Trial.

6

Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.

Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, Schuster MW, Niesvizky R, Muss D, Fiore J, Kroll S, Tidmarsh G, Vallabhajosula S, Goldsmith SJ. Leonard JP, et al. Among authors: niesvizky r. J Clin Oncol. 2005 Aug 20;23(24):5696-704. doi: 10.1200/JCO.2005.14.803. J Clin Oncol. 2005. PMID: 16110029 Clinical Trial.

7

Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.

Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, Knowles DM, Lane J, Chen-Kiang S. Ely S, et al. Among authors: niesvizky r. Cancer Res. 2005 Dec 15;65(24):11345-53. doi: 10.1158/0008-5472.CAN-05-2159. Cancer Res. 2005. PMID: 16357141

8

Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.

Dosik AD, Coleman M, Kostakoglu L, Furman RR, Fiore JM, Muss D, Niesvizky R, Shore T, Schuster MW, Stewart P, Vallabhajosula S, Goldsmith SJ, Leonard JP. Dosik AD, et al. Among authors: niesvizky r. Cancer. 2006 Feb 1;106(3):616-22. doi: 10.1002/cncr.21606. Cancer. 2006. PMID: 16362977 Free article.

9

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, Chen-Kiang S. Baughn LB, et al. Among authors: niesvizky r. Cancer Res. 2006 Aug 1;66(15):7661-7. doi: 10.1158/0008-5472.CAN-06-1098. Cancer Res. 2006. PMID: 16885367

10

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.

Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse RN, Ely S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M. Niesvizky R, et al. Br J Haematol. 2007 Sep;138(5):640-3. doi: 10.1111/j.1365-2141.2007.06698.x. Br J Haematol. 2007. PMID: 17686058 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

176 results

Search Page